We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01652287
First Posted: July 30, 2012
Last Update Posted: June 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Penn State University
Information provided by (Responsible Party):
Daniel Merenstein, Georgetown University
  Purpose

The investigators believe a readily available drink containing a high dose of probiotics has the potential to improve compliance through many of these mechanisms. This product also has the potential to positively impact the health of children and adults around the world, as yogurt will likely be more appealing to both children and their parents for long term consumption than pharmaceutical-like preparations. In addition to the benefits associated with the consumption of probiotics, there is an increased health benefit from consuming yogurt, a nutrient dense food.

More specifically, the rationale for this Phase I study is to determine safety of this yogurt drink and comply with FDA recommendations pertaining to an Investigational New Drug application. The investigators hypothesize that BB-12 is safe in generally healthy children ages 1-5 years.


Condition Intervention Phase
Children Drug: BB-12 supplemented strawberry yogurt Other: Strawberry flavored yogurt Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Yogurt Beverages as a Vehicle to Deliver High Dose Probiotics

Further study details as provided by Daniel Merenstein, Georgetown University:

Primary Outcome Measures:
  • Number of Adverse Events [ Time Frame: Days 0-180 ]
    The primary outcome is to assess the safety of BB-12® yogurt when consumed by generally healthy children. To achieve this aim, data on adverse events will be collected from diaries; calls to the 24-hour advice line; and research assistant phone calls on days 6, 11, 15 and 180, ±2 days. All adverse events will be tabulated by type and charted over time.


Other Outcome Measures:
  • Changes in Composition of the Microbial Community [ Time Frame: Day 10 ]
    The secondary aim was to evaluate the influence of BB-12®-supplemented yogurt and control yogurt on the fecal microbiota of participants and determine any changes in the composition of the microbial community.


Enrollment: 62
Study Start Date: February 2013
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: BB-12 supplemented yogurt
Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
Drug: BB-12 supplemented strawberry yogurt
Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
Placebo Comparator: Strawberry flavored yogurt
Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
Other: Strawberry flavored yogurt
Placebo, strawberry yogurt, 4 ounces taken orally for 10 days

Detailed Description:

Probiotics are live microorganisms that, when administered in sufficient amounts, may improve health. A common use for probiotics is in addressing gastrointestinal issues, such as antibiotic-associated diarrhea (AAD). As an alternative to supplements, probiotics are also included as ingredients in fermented dairy products to produce functional foods, which are foods providing health benefits beyond their nutritional value. Yogurt, for example, is a fermented milk product often considered a functional food. One of the most commonly used probiotics is Bifidobacterium animalis ssp. lactis (BB-12).

Our Primary Aim in Years 1-2 is to conduct a pediatric randomized controlled study to establish the safety of BB-12 fortified yogurt in children. Our Secondary Aims are to examine the fecal microbiota of children prior to, during and following consumption of probiotics. This study will evaluate whether a well-defined, probiotic-containing yogurt can safely be used as an effective delivery vehicle for probiotics. This study is important to help advance probiotic research forward in a systematic, well-accepted manner. Our long-term goal is to create yogurt with sufficient probiotic dosages to positively impact many different aspects of childhood and adult health.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria for parents/caregivers are:

  1. Ability to read, speak and write English or Spanish
  2. Access to a refrigerator for proper storage of drink
  3. Telephone access

Inclusion criteria for children are:

1. Are between the ages of 1 and 5 years

Exclusion Criteria:

  1. Developmental delays
  2. Any chronic condition, such as diabetes or asthma, that requires medication
  3. Prematurity, birth weight < 2,500 grams
  4. Congenital anomalies
  5. Failure to thrive
  6. Allergy to strawberry
  7. Active diarrhea (defined as three or more loose stools for two consecutive days)
  8. Any other medicines used except anti-pyretic medicines (to reduce fever) [excluding as needed medications]
  9. Parental belief of lactose intolerance
  10. History of heart disease, including valvulopathies or cardiac surgery, any implantable device or prosthetic
  11. History of gastrointestinal surgery or disease
  12. Milk-protein allergy
  13. Allergy to any component of the product or the yogurt vehicle
  14. During the baseline physical exam, have an oxygen saturation rate <96% and respiratory and pulse rate outside the normal range per their age.

Parents/caregivers will also be asked to refrain from giving their child any probiotic foods or supplements during the entire 2 weeks of the active intervention period, and 2 weeks before day 1 of starting the yogurt. Parents will be supplied with a list of products to avoid.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01652287


Locations
United States, District of Columbia
Georgetown University Department of Family Medicine, Research Division
Washington, D.C., District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
Penn State University
Investigators
Principal Investigator: Daniel J Merenstein, MD Georgetown University
  More Information

Additional Information:
Responsible Party: Daniel Merenstein, Principal Investigator, Georgetown University
ClinicalTrials.gov Identifier: NCT01652287     History of Changes
Other Study ID Numbers: 3U01AT003600-02S1 ( U.S. NIH Grant/Contract )
First Submitted: July 5, 2012
First Posted: July 30, 2012
Results First Submitted: January 19, 2017
Results First Posted: March 13, 2017
Last Update Posted: June 1, 2017
Last Verified: April 2017